Amylyx Pharmaceuticals Completes Enrollment for Avexitide Phase 3 Lucidity Trial

Amylyx Pharmaceuticals has completed enrollment in the Phase 3 Lucidity trial for avexitide, a treatment for post-bariatric hypoglycemia. The trial involves 78 participants and topline data is expected in Q3 2026. Avexitide is expected to launch in 2027 if approved. The company's shares have been boosted by positive investor and expert feedback, leading to an increased probability of success estimate for the avexitide program.